Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JNJ-89495120 · 1 trial · 1 indication
The MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The scale consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition.
| Arm | Type | Description |
|---|---|---|
| Arm 1: JNJ-89495120 Dose A | EXPERIMENTAL | Participants will receive JNJ-89495120 dose A during the double-blind (DB) treatment phase in Period 1 and Period 2 of the study. |
| Arm 2: JNJ-89495120 Dose A and Dose B | EXPERIMENTAL | Participants will receive JNJ-89495120 dose A in Period 1 followed by JNJ-89495120 dose B in Period 2 during the DB treatment phase of the study. |
| Arm 3: Placebo Group | PLACEBO_COMPARATOR | Participants will receive placebo matched to JNJ-89495120 during the DB treatment phase in Period 1 and Period 2 of the study. |
| Name | Type | Description |
|---|---|---|
| JNJ-89495120 | DRUG | JNJ-89495120 will be administered. |
| Placebo | DRUG | Placebo will be administered. |
Inclusion Criteria: * Primary psychiatric diagnosis of recurrent major depressive disorder, without psychotic features, based on clinical assessment using diagnostic and statistical manual of mental disorders (DSM)-5 criteria and confirmed with the mini international neuropsychiatric interview (MIN...
JNJ-89495120 is an investigational small molecule being developed by Johnson & Johnson for the treatment of major depressive disorder. It is a Phase 2 clinical-stage candidate in the psychiatry therapeutic area and has not been approved by the FDA. It is being studied as a potential oral treatment option for adults with major depressive disorder.
JNJ-89495120 is being studied for the treatment of major depressive disorder in adults. The clinical program enrolled participants 18 years of age and older with a diagnosis of major depressive disorder. It is investigational and has not been approved for any indication.
JNJ-89495120 is being developed by Johnson & Johnson, which trades on the New York Stock Exchange under the ticker JNJ. The company is the sponsor of the clinical program evaluating the compound in major depressive disorder.
JNJ-89495120 is in Phase 2 clinical development. One Phase 2 trial has been completed, and no trials are currently active. The compound remains investigational and has not received FDA approval for major depressive disorder or any other indication.
JNJ-89495120 has been evaluated in one Phase 2 trial, NCT06785012, titled A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder. The trial was completed, enrolled 105 participants, and was conducted in the United States.
The Phase 2 trial of JNJ-89495120, NCT06785012, was a randomized, double-blind, placebo-controlled study in adults with major depressive disorder. It enrolled 105 participants aged 18 years and older in the United States. The study was completed and did not enroll healthy volunteers.